Hagar showcases favorable GWave non-invasive blood glucose monitor data at ATTD following FDA breakthrough device designation

The Israeli company behind the development of the GWave blood glucose monitor, HAGAR, has been showcasing its recent study results at ATTD 2022 in Spain. The glucometer was tested in trials that took place at the Sheba Medical Center in Tel Aviv, with the device holding up very well against painful finger-stick methods of measuring glucose levels and even offering more accurate results than continuous glucose monitors (CGM) that rely on data taken from interstitial fluid rather than blood. The GWave non-invasive glucometer attained a +95% level of accuracy when compared to more traditional methods (finger pricking).

This latest development comes only a few months after the GWave blood sugar measurement device was awarded a breakthrough device designation from the FDA. This should expedite the overall process of official approval for the GWave glucometer, which has already attracted millions of dollars in separate rounds of funding. While many other promising non-invasive CGM devices aim to take measurements from the interstitial fluid, HAGAR asserts that its GWave monitor will be able to painlessly extract more-accurate readings from dermis blood vessels thanks to its RF technology.

Two generations of the GWave blood glucose monitor have been mentioned: The first-generation device is apparently the third of the size of a typical smartphone while the GWave second-generation sensor, which is under development, is being designed in a manner that will enable users to integrate it with a smartwatch. No expected costs or potential release date for the non-invasive blood glucose monitor have been made public yet, but there will be millions of people with diabetes hoping for positive news to come sooner rather than later. Fortunately, HAGAR is planning on carrying out two more clinical studies later this year, starting in fall 2022.

Buy McKesson Safety Lancets on Amazon